We are excited to announce that earlier this month an article by our CEO, Dr. Andreas Scherer, was featured in Chronicle Pharmabiz. The article is focused on how Precision Medicine is becoming a reality by leveraging the advances in technology.

The excerpt below is courtesy of Chronicle Pharmabiz.

Almost 2,500 years ago, Hippocrates captured one of the key principles underlying precision medicine. He stated, “It’s far more important to know what person the disease has than what disease the person has.”  

In the 21st century, we take the understanding of the individual characteristics of a person to a new level. By leveraging information about an individual’s genome we are able to increase the effectiveness of medical treatments. The goal is to have more successful outcomes by providing targeted therapies. The cost of sequencing a genome has dramatically dropped since the first draft of the human genome sequence was published in 2001. This is a key enabler. Now, it is very much in reach for a wide range of patients to receive a gene panel analysis or even a whole exome/genome analysis. But there is more that is required. Through a collaborative effort between clinicians, pharma companies, scientists and regulatory agencies, we are working on a new framework for standard care on a global basis.

Finish reading the article here!